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Abstract Hispanics are the fastest growing ethnic minority in the USA. Among Hispanics, lack of hypertension
awareness and lack of effective blood pressure (BP) control are problematic, as are higher incidence rates of
hypertension-related co-morbidities compared with non-Hispanic populations. Moreover, there are cur-
rently no hypertension treatment guidelines that address the unique characteristics of this ethnic group. This
article discusses ethnic differences in hypertension and cardiovascular risk factors and reviews the literature
on the efficacy of antihypertensive agents in Hispanic patients, with a focus on the role of renin-angiotensin-
aldosterone system (RAAS) inhibition in themanagement of hypertension in these patients. Hypertension in
Hispanic patients can be challenging to manage, in part because this population has a higher prevalence of
obesity, diabetes, and metabolic syndrome compared with non-Hispanic whites. The presence of these co-
morbidities suggests that RAAS-inhibitor-based therapies may be particularly beneficial in this population.
However, few studies have evaluated the efficacy of antihypertensive treatments in Hispanic patients. Two
outcomes studies in hypertensive patients have shown the benefits of treating Hispanic patients with antihyper-
tensive therapy and included RAAS inhibitors as part of the treatment regimen. In addition, BP-lowering
trials have shown the antihypertensive efficacy of angiotensin-converting enzyme inhibitors, angiotensin II
receptor blockers, and direct renin inhibitors, although data on the latter are more limited. Additional
studies are needed to more thoroughly evaluate the effects of RAAS inhibitors (and other drug classes) on
outcomes and BP lowering in the Hispanic hypertensive population.
REVIEWARTICLE Am J Cardiovasc Drugs 2012; 12 (3): 165-1781175-3277/12/0003-0165/$49.95/0
Adisª 2012 Springer International Publishing AG. All rights reserved.
1. Introduction
Hispanic Americans (i.e. individuals of Mexican, Cuban,
PuertoRican,Dominican, SouthAmerican, orCentralAmerican
descent, or descendants of other Spanish cultures or races) are
the youngest and fastest growing ethnicminority in theUSA. In
2006, Hispanics made up 15% of the US population, and this
number is expected to grow to 24% by 2050.[1] Studies have
shown that Hispanic Americans have an increased cardiovas-
cular risk compared with non-Hispanic Whites.[2,3] Therefore,
it is important for US healthcare providers to be aware of
cardiovascular health characteristics that may be unique to this
subset of the population. As this segment of the population
continues to grow, the financial burden of managing cardio-
vascular disease will increase as well. Cardiovascular disease
accounts for the single largest proportion of both direct and
indirect US healthcare costs annually, with costs estimated at
roughly $300 billion in 2008 and rising rapidly.[4] By 2030, these
costs are projected to exceed $800 billion annually.[4]
Hypertension is the most common risk factor for cardiovas-
cular disease, surpassing smoking, obesity, and diabetes melli-
tus, and is a significant predictor of premature death and
cardiovascular disability.[4] According to 2008 estimates, 18%
of Hispanic adults ‡18 years of age have been diagnosed with
hypertension compared with 27% of non-Hispanic Whites and
32% of non-Hispanic Blacks.[5] However, in middle-aged and
older adults (45–84 years), the crude incidence rate of hyper-
tension per 1000 person-years was higher in Hispanics com-
pared with non-Hispanic Whites (65.7 vs 56.8).[6] Moreover,
compared with non-Hispanics, Hispanics are less likely to be
aware of their hypertension, and are less likely to have their
blood pressure (BP) adequately controlled.[2,7] Consequently,
hypertension-relatedmortality rates have been increasing faster
for certain Hispanic subgroups than for other ethnic groups.
For example, between 1995 and 2002, hypertension-related mor-
tality rates increased by 31% among Mexican Americans and
by 46% among other Hispanic Americans (excluding Puerto
Ricans and Cubans) compared with 27% among non-Hispanic
Whites.[8]
Unless steps are taken to increase the awareness of hyper-
tension among Hispanics, this trend of increasing hyper-
tension-related mortality is likely to continue. This appears to
be the case particularly in younger individuals. Bersamin and
colleagues,[9] for example, observed that Mexican Americans
between 25 and 34 years of age were less likely to be aware of
their hypertension compared withMexican Americans between
75 and 84 years of age (odds ratio, 5.5 [95% confidence interval
(CI), 1.7, 17.5], p < 0.001).
There are abundant data regarding the treatment of hyper-
tension in the general population and in the Black population,
which have resulted in the development of evidence-based
treatment guidelines for these groups.[10,11] However, relatively
few studies have evaluated Hispanic populations or have been
adequately powered for post hoc analyses of Hispanic subsets,
and no specific treatment guidelines exist for this demographic
group.[12] While it is clear that antihypertensive therapy to
lower BP reduces cardiovascular morbidity and mortality in all
hypertensive populations, it is unclear which antihypertensive
medications are safest and most effective in Hispanics. In many
cases, treatment with two ormore different classes of antihyper-
tensivemedications is necessary, and very few data are available
about which combinations are most beneficial in Hispanics.[12]
This article discusses ethnic differences in BP and cardiovas-
cular risk factors, reviews the literature on the efficacy of anti-
hypertensive agents in Hispanic patients, and describes the role
of renin-angiotensin-aldosterone system (RAAS) inhibitors,
including direct renin inhibitors (DRIs), in the treatment of
Hispanic patients with hypertension.
2. Ethnic Differences in Cardiovascular Disease Risk
Factors, the Epidemiology of Cardiovascular Disease,
and Lifestyle Factors
2.1 Cardiovascular Disease Risk Factors: Obesity, Diabetes,
and Metabolic Syndrome
In addition to hypertension, there are high incidences of the
cardiovascular disease risk factors of obesity, diabetes, and
metabolic syndrome among Hispanics.[4] Several studies have
shown that, compared with non-Hispanic Whites, Hispanics
have a higher prevalence of these conditions and they are more
likely to be diagnosed at a younger age.[2,3,7,13] This clustering
of co-morbidities increases patients’ overall risk of cardiovascular
morbidity and mortality, and also complicates the management
of hypertension. According to data from the 1999 to 2004 Na-
tional Health and Nutrition Examination Survey (NHANES),
more than 50% of Mexican Americans with hypertension are
obese or overweight and nearly 25% are both obese or overweight
and diabetic.[9] Future projections predict that over the next
10–20 years, the prevalence of obesity and diabetes in Hispanic
Americans will increase at a faster rate than in non-Hispanic
Whites,[14] making it even more imperative that strategies are
developed to effectively manage hypertension in these patients.
The prevalence of obesity, diabetes, andmetabolic syndrome
is particularly high among Hispanic women compared with
their non-Hispanic counterparts.[4,13] The American Heart
166 Guzman
Adis ª 2012 Springer International Publishing AG. All rights reserved. Am J Cardiovasc Drugs 2012; 12 (3)
Association 2012 update on heart disease and stroke statistics
reports that amongMexican-Americanwomen and non-Hispanic
White women, respectively, the prevalence of diabetes is 17%
versus 8%, the prevalence of metabolic syndrome is 41% versus
32%, and the proportion of women who are obese or over-
weight is 75% versus 59%.[4] Given the high prevalence of these
co-morbid conditions, it is not surprising that only 38% of
Mexican-American women treated for hypertension achieve
optimal BP control, and 27% of women continue to have un-
controlled stage 2 hypertension (i.e. systolic BP ‡160mmHg
and/or diastolic BP ‡100mmHg).[9]
2.2 Epidemiology of Cardiovascular Disease
Several epidemiologic studies have shown that despite higher
rates of obesity, diabetes, and metabolic syndrome, poorer
socioeconomic status, and reduced access to health care, His-
panic ethnicity is associated with lower rates of all-cause and
cardiovascular mortality compared with non-Hispanic White
ethnicity.[15-17] Explanations for this observation, which is often
referred to as the ‘Hispanic Paradox,’ are somewhat contro-
versial. Some have cited misclassification of ethnicity in trials
and differential ascertainment of deaths by ethnicity as possible
explanations.[15,16,18,19] Others have proposed that health-
selective and return immigration, positive health-related behav-
iors, better social support and culture-specific resiliency in
Hispanic-American communities, and lower levels of subclin-
ical cardiovascular disease contribute to these findings.[20-24]
In contrast with the above, long-term findings from the San
Antonio Heart Study refute the notion of a ‘Hispanic Para-
dox.’[25] In this study, Mexican-American (n = 1438) and non-
Hispanic White (n = 921) men and women between 45 and
64 years of age at enrollment were followed for up to 20 years to
examine the relationship between ethnicity andmortality. After
adjustment for age and sex, Mexican Americans had a 50%
greater risk of all-cause mortality, a 60% greater risk of mor-
tality because of coronary artery disease, and a 70% greater risk
of cardiovascular mortality relative to non-Hispanic Whites.
Further, even after adjusting for biomedical risk factors and
socioeconomic status, these mortality hazard ratios remained
above 1.[25] When mortality data from the San Antonio Heart
Study were analyzed in the subset of participants with diabetes,
US-bornMexican Americans (n = 554) had 66% greater risks of
both all-cause and cardiovascular mortality compared with
US-born non-Hispanic Whites (n = 178).[26] Diabetes and in-
sulin use modified the mortality differential such that Mexican
Americans with diabetes who did not require insulin therapy
had the greatest mortality risks (figure 1).[25]
Studies evaluating the prevalence of other cardiovascular
and renal diseases based on ethnicity have found that Hispanics
are more likely than non-Hispanic Whites to suffer from con-
gestive heart failure[3] and end-stage renal disease.[27] Mexican-
American men and women are also more likely to have higher
low-density lipoprotein and triglyceride levels and lower high-
density lipoprotein levels than non-Hispanic White men, and
Mexican Americans are less likely to be aware of their hyper-
cholesterolemia than their non-Hispanic White counterparts.[4]
Results of the Brain Attack Surveillance in Corpus Christi
Project have also shown that stroke is more common in Mex-
ican Americans than in non-Hispanic Whites.[28]
2.3 Lifestyle Factors
In the general patient population, Hispanics tend to have
poorer BP control than non-Hispanics;[2,7] however, based on the
results of controlled clinical trials, it is unlikely that the differences
in BP control rates between Hispanics and non-Hispanics are a
result of biologic differences. In controlled clinical trial settings,
where external factors are equal and all patients have the same
access to medical care and no-cost medication, it has been ob-
served that BP control rates among Hispanics can be equal to or
better than those of non-Hispanic Whites.[29-31] Thus, in many
cases, lifestyle, economic, and cultural factors likely contribute to
Hispanic Americans’ overall level of risk for uncontrolled hy-
pertension. Effective patient education strategies are necessary to
increase awareness of risk factors associated with hypertension
and to help patients learn to modify unhealthy behaviors.
As an example, according to NHANES data from 2001
to 2006, about one-third of Mexican Americans reported no
participation in leisure-time physical activity.[7] This rate was


























Individuals with diabetes not requiring insulin
Individuals with diabetes requiring insulin
Fig. 1. San Antonio Heart Study: Cox hazard ratio models predicting all-
cause, cardiovascular disease, and coronary heart disease mortality in a
comparison of Mexican Americans with non-Hispanic Whites, stratified by
diabetes mellitus/insulin use. Reprinted from Hunt et al.[25] by permission of
Oxford University Press.
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higher than that reported in non-Hispanic Blacks.[7] Results
from the Racial and Ethnic Approaches to Community Health
Across the US 2009 risk factor survey[32] showed that fruit and
vegetable consumption was lower in Hispanic communities
than in other ethnic minority communities throughout the
USA, including non-Hispanic Black, Asian/Pacific Islander,
and American Indian communities. In this study,[32] Hispanics
also had the lowest rates of cholesterol screenings and man-
agement of high BP with antihypertensive therapy.
Acculturation and language barriers may also negatively
affect access to health care and treatment in Hispanic commu-
nities. In a study of 131 277 patients in Kaiser Permanente’s
Northern California Diabetes Registry, Traylor and colleagues[33]
found that Hispanic patients were less likely than non-Hispanic
Whites to adhere to their cardiovascular medications (49% vs
58%; p < 0.001); equally, Spanish-speaking patients were less
likely to adhere to their cardiovascular medications com-
pared with English-speaking patients (51% vs 57%; p< 0.001).
Eamranond and colleagues[34] observed that Hispanics with low
levels of acculturation to American language, values, beliefs, and
ways of life have higher rates of diabetes and hypertension, and
are more likely to have poorly controlled hypercholesterolemia.
Patient trust is higher when healthcare providers are of the
same ethnicity as the patient and when physicians can com-
municate in the patient’s native language.[35] As of 2001, only
3.3% of internal medicine physicians and 3.8% of cardiologists
in the USA were Hispanic,[36] suggesting that most Hispanic
Americans do not have access to physicians of the same eth-
nicity and may choose to rely on the advice of trusted family
and friends instead of healthcare professionals. Hispanics have
also been shown to have a strong sense of fatalism, believing that
the course of their cardiovascular disease is out of their control
and making them less motivated to adopt healthy lifestyle
changes, seek medical care, or adhere to treatment.[37] Physician
access may also be limited by the cost of care, lack of health
insurance, and limited access to regular health care.[38] According
to US Census Bureau data, in 2009, per capita income for His-
panics was approximately half that of non-Hispanic Whites
(US$15063 vs US$30 941, respectively), the poverty rate among
Hispanicswas 25.3%, and 32.4% ofHispanics did not have health
insurance compared with 12.0% of non-Hispanic Whites.[39]
3. Efficacy of Antihypertensive Agents in Hispanics:
Review of the Literature
In landmark clinical trials of antihypertensive agents for the
management of high BP and/or cardiovascular disease, patients
of Hispanic ethnicity have been under-represented.[12] Results
from the small number of antihypertensive trials that enrolled
significant numbers of Hispanic patients are also limited be-
cause ethnicity and/or race were usually self-reported,[40-42]
which may have affected the uniformity of data capture, and in
most cases no distinctions were made between Hispanic Whites
and Hispanic Blacks.
In an effort to identify available data from randomized
controlled trials that reported on the efficacy of antihyperten-
sive agents in Hispanic patients, a search of PubMed was con-
ducted for English-language articles classified as clinical trials
or randomized controlled trials published through 26 August
2011 using the terms ‘‘(Hispanic* or Latino*) and hyperten-
sion.’’ This search yielded 148 articles. Analysis of these articles
identified 17[30,31,40-54] publications involving 15 different
studies that specifically reported on the efficacy and safety of
antihypertensive agents in Hispanic patients. Additional data
from the INVEST study (table I provides full names of trial
acronyms used in this article) was also included from a pub-
lication not identified in this search.[29] In addition, the author
was aware of and included relevant data from four studies
that were presented as abstracts[55-58] at scientific meetings.
The main results from all identified articles (n = 18) and ab-
stracts (n = 4) presenting data from 19 studies are summarized
in table II.[29-31,40-58]
Only two of the studies identified were outcomes trials
that reported results for the subset of Hispanic participants:
Table I. Full trial names of study acronyms used in this article
Acronym Name
ACQUIRE Aliskiren Alone or in Combination With Hydrochlorothiazide in
PatientsWith Stage 2Hypertension to ProvideQuick Intensive
Control of Blood Pressure
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent
Heart Attack Trial
ASCENT Aliskiren+Amlodipine+HCTZ in Minority Patients With Stage 2
Hypertension
ATTAIN Aliskiren/HCTZ vs Ramipril in Obese Patients with Stage 2
Hypertension
EVALUATE Evaluation of Valsartan’s Uniqueness and 24-Hour Blood
Pressure Efficacy
INCLUSIVE Irbesartan/HCTZ Blood Pressure Reductions in Diverse
Patient Populations
INVEST International Verapamil SR/Trandolapril Study
TRINITY Triple Therapy with Olmesartan Medoxomil, Amlodipine, and
Hydrochlorothiazide in Hypertensive Patients Study
Val-MARC Valsartan-Managing Blood Pressure Aggressively and
Evaluating Reductions in High-Sensitivity C-Reactive Protein
168 Guzman
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ALLHAT[30] and INVEST.[29,31] Of these, only INVEST re-
ported statistical comparisons of efficacy in the Hispanic co-
hort compared with the non-Hispanic cohorts.[29,31] INVEST
was an important trial because it provided evidence-based
findings on the efficacy of antihypertensive agents in Hispanic
patients compared with non-Hispanic patients. When hyper-
tensive patients with coronary artery disease were treated with
either calcium channel blocker (CCB)-based therapy (verapamil+
trandolapril) or b-adrenoceptor antagonist (b-blocker)-based
therapy (atenolol + diuretic), Hispanic patients achieved better
BP control than non-Hispanic patients, and Hispanic patients
had a significantly lower risk of experiencing adverse cardio-
vascular outcomes, including non-fatal myocardial infarction,
non-fatal stroke, or death (figure 2). Addition of an angiotensin-
converting enzyme (ACE) inhibitor to CCB therapy was asso-
ciated with a decreased risk of new-onset diabetes in Hispanic
patients, while increasing doses of b-blocker and diuretic
therapy increased the risk of new-onset diabetes.[29] Results of a
separate analysis of women participating in the INVEST
trial[31] were similar to those of the overall study population.[29]
Hispanic women receiving antihypertensive therapy were more
likely to achieve BP control compared with non-HispanicWhite
women (75% vs 68%, respectively; p< 0.001), and Hispanic
women were less likely to experience non-fatal myocardial
infarction, non-fatal stroke, or all-cause death compared with
non-Hispanic White women (5.7% vs 12.3%, respectively; ad-
justed hazard ratio, 0.84 [95% CI 0.71, 0.98]).[31] The majority
(‡79%) of both Hispanic and non-Hispanic patients in the
INVEST trial required multiple agents to achieve BP goals,[29,31]
and this finding is similar to what has been shown in other
studies of populations with high levels of cardiovascular
risk.[59]
In the ALLHAT study, hypertensive patients with at least
one other coronary heart disease risk factor were randomized to
receive an ACE inhibitor, a CCB, an a1-blocker, or a thiazide
diuretic, with step-up to combination therapy as necessary.[30]
In an analysis of the effects of Hispanic ethnicity on study results,
Margolis and colleagues[30] observed that Hispanic patients
were less likely than non-Hispanics to have controlled BP
(<140/90mmHg) at baseline, but within 6–12months of follow-
up, the proportion of Hispanic patients with controlled BP
exceeded that of non-Hispanics. At 4 years of follow-up, BP
was controlled in 72% of Hispanic Whites, 69% of Hispanic
Blacks, 67% of non-HispanicWhites, and 59% of non-Hispanic
Blacks. Thus, the authors of this study concluded that His-
panic ethnicity was not associated with inferior BP control
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Results from non-cardiovascular outcomes, BP-lowering
efficacy trials identified from the search are also summarized in
table II.[40-58] In general, all of the different classes of antihyper-
tensive drugs substantially reduced BP in Hispanic patients,
and greater BP reductions were observed with combination
therapy thanwithmonotherapy. Inmost cases, a RAAS inhibitor
(ACE inhibitor, angiotensin II receptor blocker [ARB], or
DRI) was used, either alone or in combination with another
antihypertensive agent.
3.1 Benefits of Renin-Angiotensin-Aldosterone System
Inhibitor Therapy
RAAS inhibitors may be more beneficial than other classes
of antihypertensive therapy in reducing complications related
to obesity, diabetes, and metabolic syndrome, which as dis-
cussed previously are significant concerns for many Hispanic
patients.[60] Over-activation of the RAAS results in increased
vasoconstriction, increased sodium reabsorption, and increased
aldosterone secretion, all of which elevate BP. In addition, in-
creased RAAS activity can contribute to the pathophysiology
of diabetes and metabolic syndrome. Increased aldosterone
production has been shown to impair insulin signaling and in-
crease insulin resistance, and angiotensin II-mediated oxidative
stress can damage pancreatic islet cells.[60,61] Excess food intake
has also been linked to increased angiotensin II formation in
adipocytes, and body mass index is positively correlated with
plasma aldosterone and plasma renin activity levels, suggesting
a pathophysiologic association between RAAS activation and
obesity.[60] Therefore, in addition to lowering BP, antihyperten-
sive therapy with RAAS inhibitors may also improve glucose
metabolism and delay or prevent the onset of diabetes.[60,61]
RAAS inhibitors have also been shown to reduce tissue
injury and microvascular damage in patients with hypertension
and hyperglycemia.[62] For these reasons, RAAS inhibitors
are an appropriate component of first-line therapy in hyper-
tensive patients at risk for obesity, diabetes, and/or metabolic
syndrome.[60]
3.1.1 Angiotensin-Converting Enzyme (ACE) Inhibitors
Data from randomized controlled trials reporting on the
BP-lowering efficacy of ACE inhibitors inHispanic patients are
very limited. In a study examining the effects of dietary salt
intake on the efficacy of the ACE inhibitor enalapril or the
CCB isradipine, when Hispanic patients consumed more than
190mmol of sodium per day, treatment with enalapril reduced
BP by -11.4/-9.6mmHg and treatment with isradipine reduced
BP by -13.7/-8.9mmHg compared with placebo. When His-
panic patients consumed 88mmol or less of sodium per day,
treatment with enalapril reduced BP by -13.3/-7.5mmHg and
treatment with isradipine reduced BP by -10.0/-6.0mmHg
compared with placebo.[50]
Although the ALLHAT trial included the ACE inhibitor
lisinopril as one of four assigned treatments,[30] analysis of the
efficacy of the different classes of drugs (i.e. ACE inhibitor,
CCB, a1-blocker, or a thiazide diuretic) inHispanic patients has
not been reported. In the ATTAIN trial,[63] (discussed further
in the DRI section below), treatment with the ACE inhibitor
ramipril reduced mean sitting BP by -20.1/-4.9mmHg in His-
panic patients (n = 29), and 44.8% of these patients achieved BP
control.[55] Further studies are necessary to adequately evaluate
the efficacy of ACE inhibitor monotherapy or combination
therapy in Hispanic patients.
3.1.2 Angiotensin II Receptor Blockers (ARBs)
Several studies were identified that reported the efficacy of
ARBmonotherapy or combination therapy inHispanic patients.
These studies indicate that substantial proportions of Hispanic
patients treated with ARBs as part of their treatment regimen
can achieve BP goals. The largest, TRINITY (NCT00654745;
complete results posted on ClinicalTrials.gov),[64] included a
prespecified subgroup analysis of 369 Hispanic/Latino and
2122 non-Hispanic/non-Latino hypertensive patients that has
0
No. of patients
Hispanic 8045 7881 7769 7637 7309 3913 1212


























Fig. 2. INVEST (International Verapamil SR/Trandolapril Study): Kaplan-
Meier survival curve of time to primary outcome event (composite of death,
non-fatal myocardial infarction, or non-fatal stroke) by Hispanic status.
Reprinted from Cooper-DeHoff et al.[29], with permission from Elsevier.
MI =myocardial infarction.
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been published in abstract form.[56] Regardless of ethnicity, triple
therapy with olmesartan/amlodipine/hydrochlorothiazide (HCTZ)
resulted in significantly (p < 0.05) greater reductions in systolic
BP relative to dual therapy with olmesartan/amlodipine,
olmesartan/HCTZ, or amlodipine/HCTZ.[56,64] At 12 weeks,
57% ofHispanic/Latino participants in the triple-therapy group
versus 41–51% in the dual-therapy groups achieved BP goals
(<140/90mmHg or <130/80mmHg for those with diabetes or
chronic renal or cardiovascular disease). In non-Hispanics/
non-Latinos, the corresponding resultswere 66%versus 34–47%.[56]
In the INCLUSIVE trial, after 18 weeks of treatment with
irbesartan/HCTZ, 70% of non-Hispanic Whites, 66% of non-
Hispanic Blacks, and 65% of Hispanics achieved BP goals.[42]
The Val-MARC study comparing valsartan versus valsartan/
HCTZ found that in Hispanic patients with stage 2 hyperten-
sion, combination therapy lowered systolic BP by -21.7mmHg,
compared with -16.3mmHg with monotherapy.[51] Similarly,
the EVALUATE trial showed that combination therapy with
either valsartan/HCTZ or amlodipine/HCTZ effectively lowered
BP in Hispanic patients with stage 2 hypertension (reductions
of -17.9/-9.7mmHg and -14.2/-7.2mmHg, respectively).[41] In
a study evaluating triple therapy with amlodipine/valsartan/
HCTZ 10/320/12.5mg in Hispanic patients, 8 weeks of treatment
reduced mean systolic BP by -36.7mmHg in Hispanic patients
and 73% of patients achieved target BP <140/90mmHg.[53]
3.1.3 Direct Renin Inhibitors (DRIs)
The only DRI currently approved for the treatment of hy-
pertension, either asmonotherapy or in combinationwith other
antihypertensive agents, is aliskiren. In clinical studies, alis-
kiren monotherapy and combination therapy with other agents
(e.g. diuretics or amlodipine) have all been shown to sig-
nificantly reduce BP and plasma renin activity in patients with
stage 1 or stage 2 hypertension.[63,65-67] There are currently no
cardiovascular outcomes data available on the use of aliskiren
in Hispanic patients, and BP-lowering data are limited to sub-
group analyses from clinical trials. Three subgroup analyses[55,57,58]
on the BP-lowering efficacy of aliskiren monotherapy or
combination therapy with HCTZ in Hispanics were reported
in the form of abstracts. In the 12-week ACQUIRE study
(NCT00705575; complete results posted on ClinicalTrials.gov),[66]
Hispanic patients hadmean BP reductions of -35.8/-15.8mmHg
with aliskiren/HCTZ and -23.4/-9.5mmHg with aliskiren
monotherapy.[57] In the ATTAIN study (NCT00772577; com-
plete results posted on ClinicalTrials.gov),[55,63] 8 weeks of
treatmentwith aliskiren/HCTZ reducedBPby -27.7/-10.7mmHg
in Hispanic patients, compared with -20.1/-4.9mmHg with
ramipril monotherapy (p < 0.004 between treatment groups for
change in diastolic BP).[55] In the 8-week ASCENT study
(NCT00942994; complete results posted on ClinicalTrials.gov),[67]
self-identified Hispanic patients had least-square mean systolic BP
reductions of -37.1mmHg with aliskiren/amlodipine/HCTZ
versus -27.5mmHg with aliskiren/amlodipine (p < 0.0001).[58]
Corresponding results for diastolic BP were -14.7mmHg versus
-11.0mmHg (p = 0.0054).[58]
4. Considerations for Treating the Hypertensive
Hispanic Patient
For most patients, regardless of ethnicity, multiple anti-
hypertensive agents are needed to attain BP goal.[59] For ex-
ample, current guidelines from the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure[10] state that two or more antihypertensive
medications are usually required to achieve BP goals in patients
with diabetes and chronic kidney disease, and for patients
whose BP is more than 20mmHg above the systolic BP goal or
more than 10mmHg above the diastolic BP goal. For these
patients, current guidelines recommend initiation of therapy
with two agents, one of which is usually a thiazide diuretic. The
choice of a thiazide diuretic as part of an initial treatment
regimen is based on the well established observations that drugs
in this class are generally well tolerated, can prevent cardio-
vascular complications associated with hypertension, and are
usually cost effective.[10]
The combination of a diuretic with aRAAS inhibitor is often
recommended as first-line therapy in patients with stage 2 hy-
pertension, given that the RAAS is the central mediator of the
majority of hypertension-related complications and that the
RAAS is activated in response to pressure-related target-organ
damage.[10,11] Compelling indications for RAAS-inhibitor-
based combination treatment regimens in the general popula-
tion include co-morbid cardiovascular disease, diabetes, chronic
kidney disease, stroke prevention, heart failure, and coronary
artery disease risk.[10] Although data evaluating the efficacy of
RAAS-inhibitor-based therapy in Hispanics are limited, the
high prevalence of obesity, diabetes, and metabolic syndrome
in this population provides rationale for the use of this class of
antihypertensive drugs.
When treating hypertension in the Hispanic patient, physi-
cians should be aware of the typical cardiovascular clustering
that is common in this ethnic group and the treatment chal-
lenges that this creates. Results from the INVEST study suggest
that combination therapy is necessary for the majority of hy-
pertensive Hispanic patients with coronary artery disease to
achieve target BP goals and that achieving these BP goals is
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associated with significantly lower risks of adverse cardio-
vascular events.[29]
5. Summary and Conclusions
Hypertension control andhypertension-related co-morbidities
are substantial problems in the US Hispanic population. Given
that Hispanics are the fastest growing and youngest ethnic
population in the USA, strategies to prevent hypertension-
related morbidity and mortality are essential, including hyper-
tension education programs and attention to economic issues
when prescribing to this demographic group. Aggressive anti-
hypertensive strategies are needed; however, not enough has
been done to include Hispanic Americans in clinical studies in
sufficient representative numbers. Therefore, very little evidence-
based information is available in this population, and current
guidelines do not provide specific guidance for treating hyperten-
sion in Hispanic patients. Given the clustering of hypertension
with obesity, diabetes, and metabolic syndrome in Hispanics
and the role of the RAAS in the pathogenesis of these con-
ditions, RAAS-based treatments should be a cornerstone of
therapy. Studies that included subgroup analyses of Hispanic
patients have shown that treatment with RAAS inhibitors in
combination with other antihypertensive agents is associated
with substantial BP lowering; however, more data are needed to
determine whether RAAS-based treatment regimens improve
cardiovascular outcomes in this growing patient population.
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